Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE Interest Income
Income earned on cash, deposits, and investments held by the company.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $6M fell 12.2% year over year, ahead of the -30.0% change in trailing-twelve-month interest income. Sequentially, it fell 7.9% from the prior quarter. Over 3 fiscal years it compounded at +31.2% a year.
Context
- Interest income amounted to 3.7% of revenue in FY2025, down 2.8 pp from a year earlier.
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -12.2% holds above the trailing-twelve-month pace of -30.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 25M USD
- Year-over-year change
- -31.5%
- 4-year CAGR
- +89.8%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25M | -31.5% |
| FY2024 | 2024-12-31 | 36.51M | +36.8% |
| FY2023 | 2023-12-31 | 26.69M | +141.0% |
| FY2022 | 2022-12-31 | 11.07M | +474.4% |
| FY2021 | 2021-12-31 | 1.93M | — |
Interest Income vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's LTM Mar 2026 interest income of $24.17M is the 2nd highest of the 11 companies compared; the peer median is $9.21M.
- Its year-over-year change of -30.0% is the 7th highest of 10, against a peer median of -5.1%.
- Interest income amounts to 3.6% of revenue for RARE, versus a peer median of 3.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $4.68B | +6281.3% | +60.7% | 0.5% | |
| LTM Mar 2026 | $24.17M | -30.0% | +31.2% | 3.6% | |
| LTM Jun 2026 | $23.48M | +36.0% | +38.1% | 3.3% | |
| LTM Mar 2026 | $18.76M | -30.2% | +96.3% | 21.3% | |
| LTM Mar 2026 | $18.07M | -5.1% | +203.2% | 99.9% | |
| LTM Mar 2026 | $12.81M | -9.0% | +39.8% | — | |
| LTM Mar 2026 | $5.6M | +18.8% | +134.5% | 38.5% | |
| LTM Mar 2026 | $3.45M | +2031.5% | +229.8% | 3.9% | |
| LTM Mar 2026 | $1.84M | -40.4% | +46.2% | 367.5% | |
| LTM Mar 2026 | $1.04M | -74.2% | +32.8% | 1.3% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding RARE) | $9.21M | -5.1% | +60.7% | 3.9% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 351.41M | 363.33M | 434.25M | 560.23M | 673M |
| Cost of Revenue | 16.01M | 28.32M | 45.21M | 76.73M | 109M |
| Gross Profit | 335.4M | 335.01M | 389.04M | 483.5M | 564M |
| Gross Margin | 95.4% | 92.2% | 89.6% | 86.3% | 83.8% |
| Research & Development | 497.15M | 705.79M | 648.45M | 697.87M | 750M |
| Selling, General & Admin | 219.98M | 278.14M | 309.8M | 321.61M | 349M |
| Operating Expenses | 717.14M | 983.93M | 958.25M | 1.02B | 1.1B |
| Depreciation & Amortization | 13.24M | 18.22M | 26.01M | 35.54M | 35M |
| EBITDA | (410.32M) | (640.49M) | (516.45M) | (469M) | (474M) |
| EBITDA Margin | -116.8% | -176.3% | -118.9% | -83.7% | -70.4% |
| Operating Income | (381.74M) | (648.92M) | (569.21M) | (535.97M) | (535M) |
| Operating Margin | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% |
| Interest Income | 1.93M | 11.07M | 26.69M | 36.51M | 25M |
| Interest Expense | 29.42M | 43.02M | 66M | 63.04M | 62M |
| Other Income / Expenses | (71.24M) | (52.81M) | (39.26M) | (31.61M) | (36M) |
| Income Before Tax | (452.98M) | (701.73M) | (608.46M) | (567.59M) | (571M) |
| Pre-Tax Margin | -128.9% | -193.1% | -140.1% | -101.3% | -84.8% |
| Income Tax Expense | 1.04M | 5.7M | (1.83M) | 1.6M | 4M |
| Net Income | (454.03M) | (707.42M) | (606.64M) | (569.18M) | (575M) |
| Net Margin | -129.2% | -194.7% | -139.7% | -101.6% | -85.4% |
| EPS (Basic) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| EPS (Diluted) | (6.70) | (10.12) | (8.25) | (6.29) | (5.83) |
| Weighted Avg Shares | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
| Weighted Avg Shares (Diluted) | 67.8M | 69.91M | 73.54M | 90.54M | 98.6M |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.